Will Lixiana hit the 100 billion won mark for the NOAC RX?

Cumulative prescriptions in the third quarter amounted to 78.2 billion won, Last year, it exceeded 96.7 billion won and is likely to exceed 100 billion won.

Despite stagnant growth in the NOAC market, it is the only original drug whose performance has improved

Attention is focused on whether Daiichi Sanko Lixiana will become the first NOAC drug to exceed 100 billion won in annual prescription sales.

 

As of the third quarter, the cumulative prescription amount was 78.2 billion won, and if this trend continues, it is expected that prescriptions will easily exceed 100 billion won by the end of the year.

 

Lixiana's annual prescription volume exceeded KRW 100 billion, making it the only original company to grow According to UBIST, a pharmaceutical market research firm, on the 9th, Lixiana's outpatient prescription volume in the third quarter was 26.8 billion won.

 

Compared to 24.9 billion won in the third quarter of last year, it increased by 8% in one year.

 

Lixiana's cumulative prescription amount in the third quarter was 78.2 billion won.

 

The pharmaceutical industry predicts that if this trend continues, the number of prescriptions will increase to more than 100 billion won by the end of the year.

 

Lixiana recorded prescriptions worth 96.7 billion won last year.

 

In Korea, products that recorded over 100 billion won in prescriptions last year include Viatris 'Lipitor', Hanmi Pharmaceutical 'Rosuzet', HK inno.

 

N 'K-CAB', Daewoong Bio Gliatamin, Handok 'Plavix', Chongkundang Gliatirin, LG Chemical Zemimet, etc.

 

There are only 7.

 

Even though the domestic NOAC market has reached a plateau, Lixiana is the only original drug that continues to see an upward trend in prescription performance.

 

The NOAC market continued to grow rapidly until last year.

 

The NOAC market, which was 147.2 billion won in 2018, reached 225.9 billion won in 2021, reaching the 200 billion won mark.

 

Last year, the market size further expanded to 242.5 billion won.

 

However, on a quarterly basis, it appears to have slowed down since peaking in the second quarter of last year.

 

The NOAC market, which was 61.8 billion won in the second quarter of last year, decreased to 58.3 billion won in the 4th quarter.

 

This year, it stagnated at 59.3 billion won in the first quarter, 60.2 billion won in the second quarter, and 60.9 billion won in the third quarter.

 

BMS Eliquis, the second-largest product in the market, recorded prescription sales of 19.2 billion won in the third quarter.

 

It remained at a similar level to the third quarter of last year.

 

Eliquis has been recording prescription sales of around 19 billion won every quarter since the third quarter of last year.

 

Xarelto's prescription performance decreased significantly due to the release of generics and the subsequent price reduction.

 

Xarelto prescriptions in the third quarter amounted to 7.6 billion won, a 36% decrease from 11.8 billion won in the same period last year.

 

Xarelto had issued quarterly prescriptions worth more than 15 billion won until the third quarter of 2021, but prescriptions have plummeted since the launch of generics.

 

In the fourth quarter of last year, the quarterly prescription amount fell below 10 billion won and has been steadily decreasing since then.

 

Boehringer Ingelheim Pradaxa's slump is prolonged.

 

Pradaxa's prescription volume in the third quarter was 2.5 billion won, a 19% decrease compared to the same period last year.

 

Generics for Xarelto are rapidly expanding their influence.

 

The combined prescription amount for generics for Xarelto in the third quarter was 4.7 billion won.

 

It increased by 72% compared to 2.7 billion won in the third quarter of last year.

 

Its share in the rivaroxaban treatment market increased to 38%.

 

Compared to 18% in the third quarter of last year, the market share has more than doubled in one year.

 

Xarelto generics were released in large numbers in the third quarter of that year following the release of Chong Kun Dang's Riroxia in the second quarter of 2021.

 

Chong Kun Dang's Riroxia, Hanmi Pharmaceutical's Riroxban, and Samjin Pharmaceutical's Rivoxaban are competing.

 

As of the third quarter of this year, Riroxia's cumulative prescriptions were the highest at 3.3 billion won.

 

Riroxban follows this at 2.4 billion won and Rivoxaban at 2.1 billion won.

 

The remaining 30 companies had cumulative prescriptions of less than 1 billion won in the third quarter.